Some findings suggest that combination therapy with PD-1 inhibitors and apatinib improves therapeutic efficacy, mainly because tumor angiogenesis inhibits the extravasation of reactive T-cells, which form an immunosuppressive microenvironment, leading to tumor evasion of immune surveillance. The gene discussed is RPL17; the disease is neoplasm.